We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Respivant Sciences announced has dosed the first patient in the SCENIC trial, a Phase 2b study of RVT-1601 for the treatment of persistent cough in patients with idiopathic pulmonary fibrosis (IPF).